Search Results - triple+negative+breast+cancer

6 Results Sort By:
Assay to Screen Anti-metastatic Drugs
Abstract: Scientists at the NCI developed a research tool, a murine cell line model (JygMC(A)) with a reporter construct, of spontaneous metastatic mammary carcinoma that resembles the human breast cancer metastatic process in a triple negative mammary tumor. The assay is useful for screening compounds that specifically inhibit pathways involved in...
Published: 8/13/2024   |   Inventor(s): Nadia Castro, David Salomon, Frank Cuttitta
Keywords(s): ANGIOGENESIS, Cell line, Metastasis, Triple Negative Breast Cancer, tumorigenesis
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Research Materials
Use of Acetalax for Treatment of Triple Negative Breast Cancer
Abstract: Triple negative (progesterone receptor (PR)-, estrogen receptor (ER)-, human epidermal growth receptor 2 (HER2)-) breast cancer (TNBC) is an aggressive subtype that affects 15-20% of the 1.7 million cases of breast cancer occurring annually.  Currently, standard treatments of TNBC include cytotoxic chemotherapies, surgery, and radiation. However,...
Published: 4/8/2024   |   Inventor(s): William Reinhold, Matthew Garnett, Vinodh Rajapakse, Yves Pommier, Augustin Luna
Keywords(s): Acetalax, Oxyphenisatin Acetate, Pommier, TNBC, Triple Negative Breast Cancer, Uterine Cancer
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology
CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF
CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF Researchers at Stanford have developed compounds that act as potent anti-cancer drugs which selectively inhibit CDK19 over CD8 and promise a greater therapeutic index and reduced systemic toxicity. Breast cancer remains the leading cause of cancer-related death among women worldwide. Patient mortality...
Published: 7/6/2023   |   Inventor(s): Vincent Alford, Mark Smith, Michael Clarke, Jitendra Gurjar, Angera Kuo
Keywords(s): CDK19, CDK8, Compound, Selective Inhibition, Therapeutic, Treatment, Triple Negative Breast Cancer
Category(s): Technology Classifications > Biology
CDK19- SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF
CDK19- SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF Researchers at Stanford University have identified new CDK19-selective inhibitors for the treatment of triple negative breast cancer. Breast cancer remains the leading cause of cancer-related mortality among women worldwide. While early cancer detection methods such as genetic biomarker screening...
Published: 3/17/2023   |   Inventor(s): Robert Hsieh, Mark Smith, Michael Clarke, Vincent Alford, Andrew Amant
Keywords(s): CDK19, CDK8, Cyclin Dependent Kinases, Kinase Inhibitor, Triple Negative Breast Cancer
Category(s): Technology Classifications > Chemistry
METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER
METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have developed a method for treating and predicting treatment efficacy of triple negative breast cancer (TNBC). TNBC is an aggressive subtype of breast cancer that is characterized by a lack of expression of three receptors commonly...
Published: 3/17/2023   |   Inventor(s): Michael Clarke, Robert Hsieh
Keywords(s): Breast Cancer, Cancer, CDK19, Oncology, TNBC, Triple Negative Breast Cancer
Category(s): Technology Classifications > Biology
Targeting LASP1, eIF4A1, eIF4B, and CXC4 with Modulators for treating cancer
Project ID: D2019-32 Background: Breast cancer (BC) is a heterogeneous disease and is the second leading cause of death in women among the cancer mortalities. With the new estimates in 2019, 3 out of 10 women will develop BC in her lifetime and 1 in 7 will succumb to BC. Mortality in BC patients is mainly due to metastasis to the lungs, bone, and brain....
Published: 5/9/2024   |   Inventor(s): Dayanidhi Raman, Cory Howard, John Nemunaitis, F. Charles Brunicardi, Shi-He Liu, Amit Tiwari
Keywords(s): Cancer, CXCL12, CXCL8, CXCLB, CXCR4, eIF4A, LASP1, mTNBC, NACT, pCR, TNBC, Triple negative breast cancer
Category(s): Oncology